{
    "clinical_study": {
        "@rank": "137885", 
        "arm_group": [
            {
                "arm_group_label": "SB2 (proposed biosimilar to inflixmab)", 
                "arm_group_type": "Experimental", 
                "description": "SB2 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion"
            }, 
            {
                "arm_group_label": "Remicade (infliximab)", 
                "arm_group_type": "Active Comparator", 
                "description": "Remicade 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate\n      the efficacy, safety, pharmacokinetics and immunogenicity of SB2 compared to Remicade in\n      subjects with moderate to severe Rheumatoid Arthritis (RA) despite Methotrexate (MTX)\n      therapy."
        }, 
        "brief_title": "A Study Comparing SB2 to Remicade\u00ae in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy", 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed as having RA according to the revised 1987 ACR criteria for at least 6\n             months\n\n          -  Have moderate to severe active disease despite MTX therapy defined as having more\n             than or equal to six swollen joints and more than or equal to six tender joints and\n             either erythrocyte sedimentation rate (ESR, Westergren) \u2265 28 mm/h or serum C-reactive\n             protein \u2265 1.0 mg/dL\n\n          -  Must have been treated with MTX for at least 6 months prior to Randomisation and on a\n             stable dose of MTX 10-25 mg/week given at least 4 weeks prior to Screening\n\n          -  Female subjects who are not pregnant or nursing at Screening and who are not planning\n             to become pregnant from Screening until 6 months after the last dose of\n             investigational product\n\n        Exclusion Criteria:\n\n          -  Have been treated previously with any biological agents including any tumour necrosis\n             factor inhibitor\n\n          -  Have a known hypersensitivity to human immunoglobulin proteins or other components of\n             Remicade or SB2\n\n          -  Have a positive serological test for hepatitis B or hepatitis C or have a known\n             history of infection with human immunodeficiency virus\n\n          -  Have a current diagnosis of active tuberculosis\n\n          -  Have had a serious infection or have been treated with intravenous antibiotics for an\n             infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation.\n\n          -  Have any of the following conditions\n\n               1. Other inflammatory or rheumatic diseases.\n\n               2. History of any malignancy within the previous 5 years prior to Screening\n\n               3. History of lymphoproliferative disease including lymphoma.\n\n               4. History of congestive heart failure\n\n               5. Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound).\n\n               6. History of demyelinating disorders."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "584", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936181", 
            "org_study_id": "SB2-G31-RA"
        }, 
        "intervention": [
            {
                "arm_group_label": "Remicade (infliximab)", 
                "intervention_name": "Remicade (infliximab)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SB2 (proposed biosimilar to inflixmab)", 
                "intervention_name": "SB2 (proposed biosimilar to infliximab)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "Infliximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rheumatoid Arthritis", 
            "Infliximab", 
            "Biosimilar"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hristo Botev Str.", 
                        "country": "Bulgaria", 
                        "state": "Sliven", 
                        "zip": "8800"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santariskiu", 
                        "country": "Lithuania", 
                        "state": "Vilnius", 
                        "zip": "08661"
                    }, 
                    "name": "Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Lithuania"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade\u00ae in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy", 
        "overall_official": {
            "affiliation": "Medical University of Vienna", 
            "last_name": "Josef Smolen, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Bulgaria: Bulgarian Drug Agency", 
                "Lithuania: State Medicine Control Agency - Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "American College of Rheumatology 20% response criteria (ACR20)", 
            "safety_issue": "No", 
            "time_frame": "Week 30"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936181"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "ACR20", 
                "safety_issue": "No", 
                "time_frame": "Week 54"
            }, 
            {
                "measure": "American College of Rheumatology 50% response criteria (ACR50)", 
                "safety_issue": "No", 
                "time_frame": "Week 30, Week 54"
            }, 
            {
                "measure": "Disease activity score based on a 28 joint count (DAS28)", 
                "safety_issue": "No", 
                "time_frame": "Week 30, Week 54"
            }
        ], 
        "source": "Samsung Bioepis Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Bioepis Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}